NEW YORK (GenomeWeb) – Canopy Biosciences today announced an agreement with Cosmo Bio to distribute its genetic engineering products in Japan.
Under the agreement, St. Louis-based Canopy will gain access to Cosmo's Japanese academic and pharmaceutical customers for its gene editing and personalized medicine technologies. Financial and other terms of the agreement were not disclosed.
Canopy's lead product is its Tunr gene editing system, which the firm said allows researchers to control the expression of genes of interest, letting them express genes across a range from 100 percent expression to complete knockout. The company launched the product, which is based on technology licensed from Washington University in St. Louis and Johns Hopkins University, in March.
"The genetic engineering market continues to grow at a rapid pace in Japan and we anticipate that the Tunr technology will become a key factor in gene editing," Haruhisa Sakurai, president of Cosmo, said in a statement.
"We are dedicated to bringing our genetic engineering tools to researchers across the globe and expanding our footprint in Japan," Edward Weinstein, president and CEO of Canopy, said. "Cosmo Bio is an ideal distribution partner for our genetic engineering products and services due to their deep technical expertise and fantastic customer relationships."